U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07565155) titled 'Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency' on April 27.
Brief Summary: The purpose of this study is to determine the objective response rate (ORR) to lorigerlimab in patients with refractory pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) in breast cancer type 1 or 2 susceptibility protein (BRCA1/2), Partner and Localizer of BRCA2 (PALB2) and radiation sensitive protein 51 C or D (RAD51C/D).
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Pancreatic Adenocarcinoma
Homologous Recombination Deficiency
Intervention:
DRUG: ...